167 related articles for article (PubMed ID: 34362588)
1. Expression of cancer stem cell markers in tall cell variant papillary thyroid cancer identifies a molecular profile predictive of recurrence in classic papillary thyroid cancer.
Beck AC; Rajan A; Landers S; Kelley S; Bellizzi AM; Lal G; Sugg SL; Howe JR; Chan CH; Weigel RJ
Surgery; 2022 Jan; 171(1):245-251. PubMed ID: 34362588
[TBL] [Abstract][Full Text] [Related]
2. Radioactive iodine does not improve overall survival for patients with aggressive variants of papillary thyroid carcinoma less than 2 cm.
Holoubek SA; MacKinney EC; Khokar AM; Kuchta KM; Winchester DJ; Prinz RA; Moo-Young TA
Surgery; 2022 Jan; 171(1):203-211. PubMed ID: 34384604
[TBL] [Abstract][Full Text] [Related]
3. Low expression of
Yang L; Zhang X; Zhang J; Liu Y; Ji T; Mou J; Fang X; Wang S; Chen J
Future Oncol; 2022 Jan; 18(3):333-348. PubMed ID: 34756116
[TBL] [Abstract][Full Text] [Related]
4. The prognostic significance of tall cells in papillary thyroid carcinoma: A case-control study.
Stenman S; Siironen P; Mustonen H; Lundin J; Haglund C; Arola J
Tumour Biol; 2018 Jul; 40(7):1010428318787720. PubMed ID: 30010512
[TBL] [Abstract][Full Text] [Related]
5. Surgical management of T1/T2 node-negative papillary thyroid cancer with tall cell histology: Is lobectomy enough?
Woods RSR; Fitzgerald CWR; Valero C; Lopez J; Morris LGT; Cohen MA; Wong RJ; Patel SG; Ghossein RA; Tuttle RM; Shaha AR; Shah JP; Ganly I
Surgery; 2023 Jan; 173(1):246-251. PubMed ID: 36257862
[TBL] [Abstract][Full Text] [Related]
6. Tall cell variant papillary thyroid carcinoma impacts disease-free survival at the 10 % cut-point on multivariate analysis.
Samankan S; Militello L; Seo G; Everest S; O'Malley Q; Spaulding SL; Xing M; Matloob A; Beute J; Chai R; Doyle S; Urken ML; Brandwein-Weber M
Pathol Res Pract; 2022 Aug; 236():154012. PubMed ID: 35834884
[TBL] [Abstract][Full Text] [Related]
7. Tall Cell Variant of Papillary Thyroid Carcinoma: Impact of Change in WHO Definition and Molecular Analysis.
Wong KS; Higgins SE; Marqusee E; Nehs MA; Angell T; Barletta JA
Endocr Pathol; 2019 Mar; 30(1):43-48. PubMed ID: 30565013
[TBL] [Abstract][Full Text] [Related]
8. Should multifocality be an indication for completion thyroidectomy in papillary thyroid carcinoma?
Harries V; Wang LY; McGill M; Xu B; Tuttle RM; Wong RJ; Shaha AR; Shah JP; Ghossein R; Patel SG; Ganly I
Surgery; 2020 Jan; 167(1):10-17. PubMed ID: 31515125
[TBL] [Abstract][Full Text] [Related]
9. Expression of MRP1 and ABCG2 is associated with adverse clinical outcomes of papillary thyroid carcinoma with a solid component.
Ohashi R; Kawahara K; Namimatsu S; Okamura R; Igarashi T; Sugitani I; Naito Z
Hum Pathol; 2017 Sep; 67():11-17. PubMed ID: 28411177
[TBL] [Abstract][Full Text] [Related]
10.
Luo J; Zhang B; Cui L; Liu T; Gu Y
Future Oncol; 2019 Apr; 15(12):1303-1311. PubMed ID: 30757917
[No Abstract] [Full Text] [Related]
11. A novel RNA sequencing-based risk score model to predict papillary thyroid carcinoma recurrence.
He J; Tian Z; Yao X; Yao B; Liu Y; Yang J
Clin Exp Metastasis; 2020 Apr; 37(2):257-267. PubMed ID: 31792675
[TBL] [Abstract][Full Text] [Related]
12. c-Met expression in tall cell variant papillary carcinoma of the thyroid.
Nardone HC; Ziober AF; LiVolsi VA; Mandel SJ; Baloch ZW; Weber RS; Mick R; Ziober BL
Cancer; 2003 Oct; 98(7):1386-93. PubMed ID: 14508824
[TBL] [Abstract][Full Text] [Related]
13. Liquid-based cytology improves preoperative diagnostic accuracy of the tall cell variant of papillary thyroid carcinoma.
Lee SH; Jung CK; Bae JS; Jung SL; Choi YJ; Kang CS
Diagn Cytopathol; 2014 Jan; 42(1):11-7. PubMed ID: 23754825
[TBL] [Abstract][Full Text] [Related]
14. Impact of tall cell variant histology on predicting relapse and changing the management of papillary thyroid carcinoma patients.
Gunalp B; Okuyucu K; Ince S; Ayan A; Alagoz E
Hell J Nucl Med; 2017; 20(2):122-127. PubMed ID: 28697188
[TBL] [Abstract][Full Text] [Related]
15. Contemporary evaluation and management of tall cell variant of papillary thyroid carcinoma.
Cartwright S; Fingeret A
Curr Opin Endocrinol Diabetes Obes; 2020 Oct; 27(5):351-357. PubMed ID: 32701516
[TBL] [Abstract][Full Text] [Related]
16. Papillary Thyroid Cancers with Focal Tall Cell Change are as Aggressive as Tall Cell Variants and Should Not be Considered as Low-Risk Disease.
Bongers PJ; Kluijfhout WP; Verzijl R; Lustgarten M; Vermeer M; Goldstein DP; Devon K; Rotstein LE; Asa SL; Brierley JD; Tsang RW; Ezzat S; Vriens MR; Mete O; Pasternak JD
Ann Surg Oncol; 2019 Aug; 26(8):2533-2539. PubMed ID: 31115855
[TBL] [Abstract][Full Text] [Related]
17. Association of Cancer Stem Cell Markers With Aggressive Tumor Features in Papillary Thyroid Carcinoma.
Lin Z; Lu X; Li W; Sun M; Peng M; Yang H; Chen L; Zhang C; Cai L; Li Y
Cancer Control; 2015 Oct; 22(4):508-14. PubMed ID: 26678979
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive MicroRNA expression profiling identifies novel markers in follicular variant of papillary thyroid carcinoma.
Dettmer M; Perren A; Moch H; Komminoth P; Nikiforov YE; Nikiforova MN
Thyroid; 2013 Nov; 23(11):1383-9. PubMed ID: 23427895
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of BRAF mutation in thyroid papillary cancer.
Fernandez IJ; Piccin O; Sciascia S; Cavicchi O; Repaci A; Vicennati V; Fiorentino M
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):919-25. PubMed ID: 23482475
[TBL] [Abstract][Full Text] [Related]
20. Clinical behaviour of papillary thyroid cancer oncocytic variant: stage-matched comparison versus classical and tall cell variant papillary thyroid cancer.
Okuyucu K; Ince S; Cinar A; San H; Samsum M; Dizdar N; Alagoz E; Demirci I; Ozkara M; Gunalp B; Karaçalıoglu AO
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2023; 42(2):100-105. PubMed ID: 36155103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
